ABSTRACT
Background and Aim: Adropin is a hormone encoded by the Enho gene, which is associated with energy homeostasis. Preclinical studies using animal models have shown that adropin plays a role in enhancing glucose homeostasis and dyslipidemia. Lately, several studies on animal models have been performed to examine the therapeutic and pathophysiological effects of adropin in many disorders. The aim of this systematic review was to identify the ideal adropin dose in mice and rat animal models.
Materials and Methods: We systematically searched PubMed, Science Direct, and Scopus databases from 2008 to 2020. The terms used in the search were "adropin," "adropin doses in animal models," "glucose homeostasis related to adropin," and "adropin therapeutic effects on rats and mice." Articles that included non-adropin doses, in vitro studies, and factors affecting adropin levels were excluded from the study.
Results: Of the total 179 qualified studies, six studies were included. We found that a daily injection of 450 nmol/kg of adropin for 3 days might be considered the optimum dose of effect in mice, whereas injection of 2.1 μg/kg once a day for 10 successive days might be the optimal effective dose in rats.
Conclusion: Additional investigations are needed to determine the optimum dose of adropin to be used as a therapeutic intervention depending on the animal model.
Keywords: adropin, animal model, dyslipidemia, glucose homeostasis, systematic review, therapeutic dose.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.